002581 Shandong Sinobioway Biomedicine
- 8.25
- +0.06+0.73%
Shandong Sinobioway Biomedicine News
Unnamed Pharmaceuticals: Announcement on Cancelling Some Stock Options of the 2023 Stock Options Incentive Plan and Adjusting the List of Incentive Targets
Unnamed Pharmaceuticals: Supplementary Announcement on the Achievement of the Enforcement Conditions for the First Exercise Period of the 2023 Stock Options Incentive Plan
Unnamed Medicine: Legal Opinion of Zhejiang Tianzu (Shenzhen) Law Firm on Shandong Weiming Biomedical Co., Ltd. canceling some stock options and adjusting the list of incentive recipients in the 2023 Stock Option Incentive Plan
Shandong Sinobioway Biomedicine: Announcement regarding the proposed transfer of equity in a subsidiary company via public listing.
Shandong Sinobioway Biomedicine: Report on the valuation of all equity values of shareholders involved in the equity transfer of Yingkou Yingxin Chemical Technology Co., Ltd.
Shandong Sinobioway Biomedicine: Announcement on cancellation of some stock options under the 2023 Stock Options Incentive Plan
Shandong Sinobioway Biomedicine: Announcement on the fulfillment of the right conditions for the first exercise period of the 2023 Stock Options Incentive Plan
Shandong Sinobioway Biomedicine: Legal Opinion of Zhejiang Tianzu (Shenzhen) Law Firm on the fulfillment of the terms of reference of the first phase of the 2023 Stock Option Incentive Plan of Shandong Weiming Biomedical Co., Ltd. and the cancellation of some stock options
Unnamed Pharmaceuticals: Announcement on shareholders' holdings holding 5% or more of their shares not reduced at the end of the term of the plan to reduce their holdings
Unnamed Pharmaceuticals: Announcement on the Company\'s Shareholders\' Share Pledges
Unnamed Pharmaceutical: Notice on Signing the “Shandong Weiming Biomedical Industrial Park Investment, Construction and Asset Repurchase Agreement” and Accepting Guarantees from Related Parties
Unnamed Pharmaceuticals: Announcement on the expiration of the share reduction plan period for shareholders holding 5% or more of the shares and the pre-disclosure of future holdings reduction plans
Unnamed Pharmaceutical: Announcement on the completion of the grant of the 2023 Stock Option Incentive Plan
Unnamed Pharmaceuticals: Simplified Statement of Changes in Equity
Unnamed Pharmaceuticals: An indicative announcement on the completion of a judicial auction transfer of some shares of shareholders holding 5% or more and changes in shareholders\' rights
Unnamed Pharmaceuticals: Announcement on Granting Stock Options to Incentive Targets of the Company\'s 2023 Stock Options Incentive Plan
Unnamed Pharmaceuticals: Legal opinion from Zhejiang Tianzui (Shenzhen) Law Firm on the awarding of Shandong Weiming Biomedical Co., Ltd.\'s 2023 stock option incentive plan
Unnamed Pharmaceuticals: Supervisory Board\'s Review Opinions on the List of Incentives Awarded by the Company\'s 2023 Stock Option Incentive Plan
Unnamed Pharmaceuticals: Supervisory Board\'s Audit Opinion and Disclosure Statement on the Company\'s 2023 Stock Option Incentive Plan Incentive Target List
Unnamed Pharmaceuticals: Self-inspection Report on Insider Insiders and Incentive Targets of the 2023 Stock Options Incentive Plan to Trade Company Shares
Analysis
Price Target
No Data
